Pathogenesis of antiphospholipid antibody syndrome needs further exploration

摘要: Introduction Antiphospholipid antibody syndrome (APLAS) is an autoimmune thrombophilic condition with or without connective tissue diseases, most commonly systemic lupus erythematosus (SLE) manifested by vascular thrombosis fetal wastage, associated antiphospholipid antibodies (APLA). Variety of clinical features has been (APL) antibodies. Hughes and his team from Hammersmith Hospital, London, first described the in 1983 they noted that increase anticardiolipin (aCL) a cohort SLE patients was thrombosis, recurrent abortions, thrombocytopenia.1 The manifestations have expanded to include thrombocytopenia, hemolytic anemia, cardiac valve disease, pulmonary hypertension, nephropathy, skin ulcers, livedo reticularis, cognitive dysfunction, premature atherosclerosis.2 prevalence disease among different patient populations India reported be between 25.5% 51.5%.3 Compilation Pubmed studies available (Table 1) clearly shows there are gaps evidence base for APLAS its association other diseases.